Opdivo Offers Hope but Poses Challenges Too, Cautious Approach Needed to Expand Indications

The launch of Ono Pharmaceutical’s anti-PD-1 antibody Opdivo (nivolumab) last September has changed the landscape of malignant melanoma treatments in Japan. Before, patients with metastatic malignant melanoma could use Kyowa Hakko Kirin’s anticancer drug dacarbazine, but patients who could not...read more